Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Abstract:
Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Cambridge, MA | Posted on January 3rd, 2008

"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer at Mersana. "Boyd brings diverse management experience and commercial expertise in areas important to Mersana at our stage of development. His skills complement those of our existing team very well, and we anticipate his strategic leadership will be of considerable value as we advance our pipeline."

Over the past 11 years Mr. Clarke has held the role of Chairman and Chief Executive Officer at several publicly-held biotechnology companies, most recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke led the company from a platform-based discovery operation to a clinical stage development company with multiple product candidates. As President and CEO of Aviron he oversaw the Biological Licensing Application (BLA) submission for the company's lead product and ultimately secured the sale of the vaccine company to MedImmune. He also served as President and CEO of US Bioscience. Mr. Clarke began his pharmaceutical career at Merck, where he held a series of increasingly responsible positions, including President of Pasteur Merieux MSD and Vice President of Merck Vaccines. He holds a Bachelor of Science degree and a Master of Arts degree from the University of Calgary. Mr. Clarke serves on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member of the Biotechnology Industry Association (BIO).

"Mersana's Fleximer(R) technology has the potential to create safer and more efficacious cancer drugs, and the promise of the technology is now being demonstrated in their ongoing clinical studies," stated Boyd Clarke. "I'm excited by the Company's prospects and am looking forward to participating in their continued growth as Chairman."

####

About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate, which is currently in Phase 1 clinical trials and several preclinical stage oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For more information, please click here

Contacts:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139

Tel: 617.498.0020
Fax: 617.498.0109

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Gyroscope' molecules form crystal that's both solid and full of motion: New type of molecular machine designed by UCLA researchers could have wide-ranging applications in technology and science January 16th, 2018

The nanoscopic structure that locks up our genes January 16th, 2018

New exotic phenomena seen in photonic crystals: Researchers observe, for the first time, topological effects unique to an “open” system January 12th, 2018

Nanotube fibers in a jiffy: Rice University lab makes short nanotube samples by hand to dramatically cut production time January 11th, 2018

Nanomedicine

The nanoscopic structure that locks up our genes January 16th, 2018

'Decorated' stem cells could offer targeted heart repair January 11th, 2018

Rice University lab modifies nanoscale virus to deliver peptide drugs to cells, tissues January 8th, 2018

SNUH team develops new nanomaterial for thermal cancer therapy January 5th, 2018

Announcements

'Gyroscope' molecules form crystal that's both solid and full of motion: New type of molecular machine designed by UCLA researchers could have wide-ranging applications in technology and science January 16th, 2018

The nanoscopic structure that locks up our genes January 16th, 2018

New exotic phenomena seen in photonic crystals: Researchers observe, for the first time, topological effects unique to an “open” system January 12th, 2018

'Decorated' stem cells could offer targeted heart repair January 11th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Leti’s New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project